Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | IMPDH2 | P12268 | 12/20 | 0.48 |
| ▸ | IMPDH1 | P20839 | 3/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6168364 | 0.79 | IMPDH2 (0.65) | GAAIMPDH2IMPDH1AAK1LMNA | |
| SCHEMBL2898349 | 0.79 | GAA (0.53) | GAAMEN1KMT2AIMPDH2IMPDH1 | |
| SCHEMBL26465053 | 0.79 | IMPDH2 (0.48) | IMPDH2IMPDH1AAK1LMNAPKM | |
| SCHEMBL9260678 | 0.78 | IMPDH2 (0.53) | IMPDH2IMPDH1AAK1LMNAPKM | |
| SCHEMBL25033577 | 0.76 | GAA (0.53) | GAAMEN1KMT2AIMPDH2IMPDH1 | |
| SCHEMBL2427867 | 0.76 | LMNA (0.53) | GAAMEN1KMT2AIMPDH2IMPDH1 | |
| SCHEMBL16202087 | 0.76 | LMNA (0.47) | GAAMEN1KMT2AIMPDH2IMPDH1 | |
| SCHEMBL27589224 | 0.76 | GAA (0.49) | GAAMEN1KMT2AIMPDH2IMPDH1 | |
| SCHEMBL10035045 | 0.74 | IMPDH2 (0.51) | GAAMEN1KMT2AIMPDH2IMPDH1 | |
| SCHEMBL1806540 | 0.74 | IMPDH2 (0.46) | GAAMEN1KMT2AIMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-30 | — | — | US | disclosed |
| EP-1423386-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003022842-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | TNF, MMP9, MMP1 | GAA 364/4885MEN1 3166/4885KMT2A 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.